Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2027, 2028, and 2029 (P50 Clinical Trial Required)
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The National Cancer Institute is soliciting applications for P50 Research Center Grants under the Specialized Programs of Research Excellence (SPORE) initiative for fiscal years 2027 through 2029. This funding opportunity supports investigator-initiated translational research focused on improving prevention, early detection, diagnosis, and treatment of organ-specific cancers or closely related groups of cancers. Eligible projects include studies targeting cancers derived from the same organ system or those connected by common biological mechanisms critical to tumorigenesis or cancer progression. Additionally, research addressing cross-cutting themes such as pediatric cancers or epigenetics is encouraged. The research must be translational in nature, derived from human biology, and employ cellular, molecular, genetic, and other experimental approaches to achieve relevant human endpoints within the grant period. This program requires the inclusion of clinical trials as part of the proposed research activities. The SPORE grants aim to foster high-impact projects that move promising laboratory findings into clinical applications to benefit patients. Interested applicants are encouraged to submit proposals that demonstrate strong translational potential and align with the goals of advancing cancer research and treatment. The point of contact for further inquiries is Bradley T. Scroggins at the National Institutes of Health.
General Info
Agency
NAICS
Place of Performance
Not specifiedSet-Aside
Documents
(0)AI Contract Breakdown
Uniform Contract FormatNo contract breakdown available.
Cannot generate Contract Breakdown because no documents were found from this contract's source.
Timeline
Organization & Contact Information
Full Description
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) invites applications for P50 Research Center Grants for Specialized Programs of Research Excellence (SPORE). This is a re-issuance of PAR-23-284. The program will fund P50 SPORE grants to support state-of-the-art investigator-initiated translational research that will contribute to improved prevention, early detection, diagnosis, and treatment of an organ-specific cancer or a highly related group of cancers. For the purpose of this NOFO, a group of highly related cancers are those that are derived from the same organ system, such as gastrointestinal, neuroendocrine, head and neck, and other cancers. Other programmatically appropriate groups of cancers may include those centered around a common biological mechanism critical for promoting tumorigenesis and/or cancer progression in organ sites that belong to different organ systems. For example, a SPORE may focus on cancers caused by the same infectious agent or cancers promoted and sustained by dysregulation of a common signaling pathway. In addition, a SPORE may focus on cross-cutting themes such as pediatric cancers or epigenetics. The research supported through this program must be translational and must stem from research on human biology using cellular, molecular, structural, biochemical, and/or genetic experimental approaches. SPORE projects must have the goal of reaching a translational human endpoint within the project period of the grant.
